Elvitegravir

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Antiretrovirally active substance for the treatment of HIV infection. Inhibitor of the HIV integrase ( strand transfer inhibitor). Chemically, it is a compound reminiscent of quinolone antibiotics, but has no antibacterial activity and no quinolone-associated side effects.

Dosage and method of useThis section has been translated automatically.

According to ongoing phase III studies: 1-2 times/day 50-125 mg each in combination with 100 mg ritonavir and/or an active protease inhibitor.

Undesirable effectsThis section has been translated automatically.

Rarely nausea, dizziness, headaches, diarrhoea and fever. Due to the study situation no long-term data are available.

Note(s)This section has been translated automatically.

Remember! Currently (as of 6/2009) Elvitegravir is only available via an Expanded Access Program for patients with viral resistance to at least one drug of the substance classes NRTI, NNRTI and PI!

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer